Phase II study of idarubicin administered i.v. to pediatric patients with acute lymphoblastic leukemia.
A total of 17 pediatric patients with pretreated acute lymphoblastic leukemia were included in a phase II study of idarubicin. Four of 16 complete remissions were obtained, confirming the activity of the drug in this indication. Toxicity was acceptable, though caution is needed in patients who have already received high cumulative doses of anthracyclines.
D000293:Adolescent; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003630:Daunorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin; D007223:Infant; D007231:Infant, Newborn; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008297:Male; D012074:Remission Induction
D000903:Antibiotics, Antineoplastic; D015255:Idarubicin; D003630:Daunorubicin